Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The symptoms of Benign Prostatic Hyperplasia (BPH) include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream.
The Benign Prostatic Hyperplasia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.
Benign Prostatic Hyperplasia Pipeline Products Market Segmentation by Targets
The key targets in the Benign Prostatic Hyperplasia pipeline products market are cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 1A Adrenergic Receptor, 3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2, Alpha 1D Adrenergic Receptor, Alpha 1B Adrenergic Receptor, Androgen Receptor, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1, Alpha 1 Adrenergic Receptor, Aromatase, and others.
Benign Prostatic Hyperplasia Pipeline Products Market Analysis by Targets
For more target insights into the Benign Prostatic Hyperplasia pipeline products market, download a free report sample
Benign Prostatic Hyperplasia Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Benign Prostatic Hyperplasia pipeline products market are cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Alpha 1A Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 2 Inhibitor, Alpha 1D Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1 Inhibitor, Alpha 1B Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Androgen Receptor Agonist, and Androgen Receptor Antagonist, and others.
Benign Prostatic Hyperplasia Pipeline Products Market Analysis by MoA
For more MoA insights into the Benign Prostatic Hyperplasia pipeline products market, download a free report sample
Benign Prostatic Hyperplasia Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the BPH pipeline products market are oral, intraprostatic, intradermal, intravitreal, rectal, subcutaneous, and transdermal.
Benign Prostatic Hyperplasia Pipeline Products Market Analysis by RoA
For more RoA insights into the Benign Prostatic Hyperplasia pipeline products market, download a free report sample
Benign Prostatic Hyperplasia Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the BPH pipeline products market are small molecule, fusion protein, subunit vaccine, and synthetic peptide.
Benign Prostatic Hyperplasia Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Benign Prostatic Hyperplasia pipeline products market, download a free report sample
BPH Pipeline Products Market – Competitive Landscape
Some of the leading companies in the BPH pipeline products market are Chengdu Dikang Pharmaceuticals Co Ltd, DongKoo Bio & Pharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, AiViva BioPharma Inc, Aphios Corp, Aquestive Therapeutics Inc, ASKA Pharmaceutical Holdings Co Ltd, BCWorld Pharm Co Ltd, Boryung Pharmaceutical Co Ltd, and Chong Kun Dang Pharmaceutical Corporation.
Benign Prostatic Hyperplasia Pipeline Products Market Analysis by Companies
To know more about the leading players in the Benign Prostatic Hyperplasia pipeline products market, download a free report sample
Benign Prostatic Hyperplasia Pipeline Products Market Report Overview
Key Targets | cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 1A Adrenergic Receptor, 3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2, Alpha 1D Adrenergic Receptor, Alpha 1B Adrenergic Receptor, Androgen Receptor, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1, Alpha 1 Adrenergic Receptor, Aromatase, and Others |
Key Mechanisms of Action | cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Alpha 1A Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 2 Inhibitor, Alpha 1D Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1 Inhibitor, Alpha 1B Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Androgen Receptor Agonist, and Others |
Key Routes of Administration | Oral, Intraprostatic, Intradermal, Intravitreal, Rectal, Subcutaneous, and Transdermal |
Key Molecule Type | Small Molecule, Fusion Protein, Subunit Vaccine, and Synthetic Peptide |
Leading Companies | Chengdu Dikang Pharmaceuticals Co Ltd, DongKoo Bio & Pharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, AiViva BioPharma Inc, Aphios Corp, Aquestive Therapeutics Inc, ASKA Pharmaceutical Holdings Co Ltd, BCWorld Pharm Co Ltd, Boryung Pharmaceutical Co Ltd, and Chong Kun Dang Pharmaceutical Corporation |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Aphios Corp
Aquestive Therapeutics Inc
ASKA Pharmaceutical Holdings Co Ltd
BCWorld Pharm Co Ltd
Boryung Pharmaceutical Co Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Curadis GmbH
DongKoo Bio & Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
GemVax & KAEL Co Ltd
Genu Pharma Co Ltd
Geropharm
Hanmi Pharmaceuticals Co Ltd
Jiangsu Kangyuan Pharmaceutical Co Ltd
Kwang Dong Pharmaceutical Co Ltd
Nymox Pharmaceutical Corp
Sentan Pharma Inc
ValiRx Plc
Veru Inc
XuanZhu Biological Technology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Benign Prostatic Hyperplasia pipeline products market?
The key targets in the Benign Prostatic Hyperplasia pipeline products market are cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 1A Adrenergic Receptor, 3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2, Alpha 1D Adrenergic Receptor, Alpha 1B Adrenergic Receptor, Androgen Receptor, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1, Alpha 1 Adrenergic Receptor, Aromatase, and others.
-
What are the key mechanisms of action in the Benign Prostatic Hyperplasia pipeline products market?
The key mechanisms of action in the Benign Prostatic Hyperplasia pipeline products market are cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Alpha 1A Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 2 Inhibitor, Alpha 1D Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase 1 Inhibitor, Alpha 1B Adrenergic Receptor Antagonist, 3 Oxo 5 Alpha Steroid 4 Dehydrogenase Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Androgen Receptor Agonist, and others.
-
What are the key routes of administration in the Benign Prostatic Hyperplasia pipeline products market?
The key routes of administration in the BPH pipeline products market are oral, intraprostatic, intradermal, intravitreal, rectal, subcutaneous, and transdermal.
-
What are the key molecule types in the Benign Prostatic Hyperplasia pipeline products market?
The key molecule types in the Benign Prostatic Hyperplasia pipeline products market are small molecule, fusion protein, subunit vaccine, and synthetic peptide.
-
Which are the leading companies in the BPH pipeline products market?
The leading companies in the BPH pipeline products market are Chengdu Dikang Pharmaceuticals Co Ltd, DongKoo Bio & Pharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, AiViva BioPharma Inc, Aphios Corp, Aquestive Therapeutics Inc, ASKA Pharmaceutical Holdings Co Ltd, BCWorld Pharm Co Ltd, Boryung Pharmaceutical Co Ltd, and Chong Kun Dang Pharmaceutical Corporation.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Women's Health reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)